2020 ASCO Virtual Direct™ Highlights

 

2020 ASCO Virtual Direct™ Highlights
C

2020 ASCO Pancreatic Cancer Update: Does Gemcitabine + Nab-paclitaxel Improve Complete Pathologic Response in Resectable Disease?

By 2020 ASCO Virtual Direct™ Highlights FEATURING Caio Rocha Lima
By 2020 ASCO Virtual Direct™ Highlights FEATURING Caio Rocha Lima
248 views
July 14, 2020
0 Comments
Login to view comments. Click here to Login

Featured Video

20:09
AstraZeneca Oncology

Management Strategies for Anemia in First-line Maintenance Therapy f…

Feat. D. Czel, C. Arn

Featured Video

21:09
Exelixis

Primary Analysis and Follow-up Data of a Combination Therapy in 1L a…

Feat. S. Ratnam
GI
11:33
2020 ASCO Virtual Direct™ Highlights

2020 ASCO Update on Locoregional CRC: 3 vs. 6 Months of Adjuvant Oxa…

Feat. L. Connell
09:21
2020 ASCO Virtual Direct™ Highlights

2020 ASCO Update on Advanced CRC: Should Pembrolizumab Be The New So…

Feat. L. Connell
14:43
2020 ASCO Virtual Direct™ Highlights

2020 ASCO Update on Advanced CRC: Is Recently FDA Approved Encorafen…

Feat. L. Connell
12:38
2020 ASCO Virtual Direct™ Highlights

2020 ASCO Pancreatic Cancer Update: Does Gemcitabine + Nab-paclitaxe…

Feat. C. Lima
08:03
2020 ASCO Virtual Direct™ Highlights

2020 ASCO HCC Update: Is Tremelimumab + Durvalumab Effective, Tolera…

Feat. C. Lima
11:08
2020 ASCO Virtual Direct™ Highlights

2020 ASCO Update on Gastric & Esophageal: Does the Addition of P…

Feat. C. Lima